Business
First use of Speedboat® UltraSlim in Latin America
First use of Speedboat® UltraSlim in Latin America.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n\nCreo Medical Group plc\n(\"Creo\" the \"Company\" or the \"Group\")\n \nFirst use of Speedboat® UltraSlim in Latin America\n12 patients treated in three days\n \nCreo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that its latest device, Speedboat® UltraSlim, has now been successfully used in Latin America for the first time.\n \nSpeedboat® UltraSlim was used at the Ecuadorian Institute of Digestive Diseases (\"IECED\") in late December, where Dr Carlos Robles Medranda, Dr Michel Kahaleh and Dr Eduardo Albeniz, supported by the Creo clinical team, performed 12 procedures using Speedboat® UltraSlim over three days, as well as performing the first ever F-POEM procedure with the device. F-POEM (Endoscopic Fundoplication Peroral Endoscopic Myotomy) is a minimally invasive endoscopic procedure used to treat oesophageal motility disorders in patients who are prone to gastroesophageal reflux.\n \nFollowing the limited market release of Speedboat® UltraSlim in December 2023 the device has been successfully used in multiple clinical applications and was used in the UK, USA to treat precancerous lesions in the colon, oesophagus and stomach, in addition to performing oesophageal and gastric POEM procedures (a procedure which addresses swallowing disorders and gastroparesis).\n \nCarlos Robles-Medranda, Head of the Endoscopy Service at IECED, said: \"I had the privilege of hosting these distinguished physicians, facilitating the successful execution of 12 procedures over three days using Speedboat UltraSlim. The excitement around the device was noticeable, and we eagerly anticipate the positive impact it will have on enhancing our patient pathways as we look to address an increased number of cases.\"\n \nDr Michel Kahaleh, who performed many of these procedures at IECED, commented: \"From the very first time when I saw the device, I knew that it was born to do POEM procedures. It allowed me to glide over the muscularis when tunnelling. Once you have acquired the knowledge to use this technology, you're really going to save procedure time. The technology allows the endoscopist to complete an F-POEM procedure with a single device, whereas previously it required three different devices.\"\n \nCraig Gulliford, Chief Executi...